A combination of Dihydroartemisinin and Venetoclax enhances antitumor effect in AML via C-MYC/BCL-XL/MCL-1 triple targeting
Abstract Background Acute myeloid leukemia (AML) is associated with high rates of resistance to standard therapies, necessitating the exploration of novel treatment strategies. Venetoclax (VEN) has shown efficacy in AML, yet drug resistance remains a significant challenge. This study aims to explore...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-04-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02242-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850202726576685056 |
|---|---|
| author | Fenglin Li Yao Chen Haihui Zhuang Renzhi Pei Yuyu Lu Dong chen Shuangyue Li Peipei Ye Jiaying lian Ying Lu |
| author_facet | Fenglin Li Yao Chen Haihui Zhuang Renzhi Pei Yuyu Lu Dong chen Shuangyue Li Peipei Ye Jiaying lian Ying Lu |
| author_sort | Fenglin Li |
| collection | DOAJ |
| description | Abstract Background Acute myeloid leukemia (AML) is associated with high rates of resistance to standard therapies, necessitating the exploration of novel treatment strategies. Venetoclax (VEN) has shown efficacy in AML, yet drug resistance remains a significant challenge. This study aims to explore the synergistic effects of combining dihydroartemisinin (DHA) with VEN to improve therapeutic outcomes in AML. Methods AML cell lines and primary cells from AML patients were treated with various concentrations of DHA, VEN and their combined regimen. The cytotoxic effects were evaluated using MTS assays, flow cytometry for apoptosis analysis, and cell cycle assessments. Protein levels of caspase-3, PARP, MCL-1, BCL-XL and C-MYC were analyzed to elucidate the underlying mechanisms of the observed synergy. Results The combination of VEN and DHA demonstrated a significant synergistic cytotoxic effect on AML cells, characterized by reduced cell proliferation, induced apoptosis, and cell cycle arrest in the G0/G1 phase. Mechanistically, the synergy was associated with increased levels of cleaved caspase-3 and PARP, along with the downregulation of anti-apoptotic proteins MCL-1 and BCL-XL. Additionally, the combined treatment led to a significant decrease in C-MYC expression. This synergistic effect was consistently observed across all primary AML patient samples analyzed. Conclusion The findings suggest that the combination of VEN and DHA exerts synergistic anti-leukemic effects by targeting BCL-XL, MCL-1 and C-MYC, offering a promising therapeutic strategy for AML. |
| format | Article |
| id | doaj-art-4831e79ce991401488ac99c22f94be33 |
| institution | OA Journals |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-4831e79ce991401488ac99c22f94be332025-08-20T02:11:42ZengSpringerDiscover Oncology2730-60112025-04-0116111010.1007/s12672-025-02242-7A combination of Dihydroartemisinin and Venetoclax enhances antitumor effect in AML via C-MYC/BCL-XL/MCL-1 triple targetingFenglin Li0Yao Chen1Haihui Zhuang2Renzhi Pei3Yuyu Lu4Dong chen5Shuangyue Li6Peipei Ye7Jiaying lian8Ying Lu9Department of Hematology, The Affiliated People’s Hospital of Ningbo UniversityDepartment of Hematology, The Affiliated People’s Hospital of Ningbo UniversityDepartment of Hematology, The Affiliated People’s Hospital of Ningbo UniversityDepartment of Hematology, The Affiliated People’s Hospital of Ningbo UniversityDepartment of Hematology, The Affiliated People’s Hospital of Ningbo UniversityDepartment of Hematology, The Affiliated People’s Hospital of Ningbo UniversityDepartment of Hematology, The Affiliated People’s Hospital of Ningbo UniversityDepartment of Hematology, The Affiliated People’s Hospital of Ningbo UniversityDepartment of Hematology, The Affiliated People’s Hospital of Ningbo UniversityDepartment of Hematology, The Affiliated People’s Hospital of Ningbo UniversityAbstract Background Acute myeloid leukemia (AML) is associated with high rates of resistance to standard therapies, necessitating the exploration of novel treatment strategies. Venetoclax (VEN) has shown efficacy in AML, yet drug resistance remains a significant challenge. This study aims to explore the synergistic effects of combining dihydroartemisinin (DHA) with VEN to improve therapeutic outcomes in AML. Methods AML cell lines and primary cells from AML patients were treated with various concentrations of DHA, VEN and their combined regimen. The cytotoxic effects were evaluated using MTS assays, flow cytometry for apoptosis analysis, and cell cycle assessments. Protein levels of caspase-3, PARP, MCL-1, BCL-XL and C-MYC were analyzed to elucidate the underlying mechanisms of the observed synergy. Results The combination of VEN and DHA demonstrated a significant synergistic cytotoxic effect on AML cells, characterized by reduced cell proliferation, induced apoptosis, and cell cycle arrest in the G0/G1 phase. Mechanistically, the synergy was associated with increased levels of cleaved caspase-3 and PARP, along with the downregulation of anti-apoptotic proteins MCL-1 and BCL-XL. Additionally, the combined treatment led to a significant decrease in C-MYC expression. This synergistic effect was consistently observed across all primary AML patient samples analyzed. Conclusion The findings suggest that the combination of VEN and DHA exerts synergistic anti-leukemic effects by targeting BCL-XL, MCL-1 and C-MYC, offering a promising therapeutic strategy for AML.https://doi.org/10.1007/s12672-025-02242-7AML VENDHAMCL-1C-MYC |
| spellingShingle | Fenglin Li Yao Chen Haihui Zhuang Renzhi Pei Yuyu Lu Dong chen Shuangyue Li Peipei Ye Jiaying lian Ying Lu A combination of Dihydroartemisinin and Venetoclax enhances antitumor effect in AML via C-MYC/BCL-XL/MCL-1 triple targeting Discover Oncology AML VEN DHA MCL-1 C-MYC |
| title | A combination of Dihydroartemisinin and Venetoclax enhances antitumor effect in AML via C-MYC/BCL-XL/MCL-1 triple targeting |
| title_full | A combination of Dihydroartemisinin and Venetoclax enhances antitumor effect in AML via C-MYC/BCL-XL/MCL-1 triple targeting |
| title_fullStr | A combination of Dihydroartemisinin and Venetoclax enhances antitumor effect in AML via C-MYC/BCL-XL/MCL-1 triple targeting |
| title_full_unstemmed | A combination of Dihydroartemisinin and Venetoclax enhances antitumor effect in AML via C-MYC/BCL-XL/MCL-1 triple targeting |
| title_short | A combination of Dihydroartemisinin and Venetoclax enhances antitumor effect in AML via C-MYC/BCL-XL/MCL-1 triple targeting |
| title_sort | combination of dihydroartemisinin and venetoclax enhances antitumor effect in aml via c myc bcl xl mcl 1 triple targeting |
| topic | AML VEN DHA MCL-1 C-MYC |
| url | https://doi.org/10.1007/s12672-025-02242-7 |
| work_keys_str_mv | AT fenglinli acombinationofdihydroartemisininandvenetoclaxenhancesantitumoreffectinamlviacmycbclxlmcl1tripletargeting AT yaochen acombinationofdihydroartemisininandvenetoclaxenhancesantitumoreffectinamlviacmycbclxlmcl1tripletargeting AT haihuizhuang acombinationofdihydroartemisininandvenetoclaxenhancesantitumoreffectinamlviacmycbclxlmcl1tripletargeting AT renzhipei acombinationofdihydroartemisininandvenetoclaxenhancesantitumoreffectinamlviacmycbclxlmcl1tripletargeting AT yuyulu acombinationofdihydroartemisininandvenetoclaxenhancesantitumoreffectinamlviacmycbclxlmcl1tripletargeting AT dongchen acombinationofdihydroartemisininandvenetoclaxenhancesantitumoreffectinamlviacmycbclxlmcl1tripletargeting AT shuangyueli acombinationofdihydroartemisininandvenetoclaxenhancesantitumoreffectinamlviacmycbclxlmcl1tripletargeting AT peipeiye acombinationofdihydroartemisininandvenetoclaxenhancesantitumoreffectinamlviacmycbclxlmcl1tripletargeting AT jiayinglian acombinationofdihydroartemisininandvenetoclaxenhancesantitumoreffectinamlviacmycbclxlmcl1tripletargeting AT yinglu acombinationofdihydroartemisininandvenetoclaxenhancesantitumoreffectinamlviacmycbclxlmcl1tripletargeting AT fenglinli combinationofdihydroartemisininandvenetoclaxenhancesantitumoreffectinamlviacmycbclxlmcl1tripletargeting AT yaochen combinationofdihydroartemisininandvenetoclaxenhancesantitumoreffectinamlviacmycbclxlmcl1tripletargeting AT haihuizhuang combinationofdihydroartemisininandvenetoclaxenhancesantitumoreffectinamlviacmycbclxlmcl1tripletargeting AT renzhipei combinationofdihydroartemisininandvenetoclaxenhancesantitumoreffectinamlviacmycbclxlmcl1tripletargeting AT yuyulu combinationofdihydroartemisininandvenetoclaxenhancesantitumoreffectinamlviacmycbclxlmcl1tripletargeting AT dongchen combinationofdihydroartemisininandvenetoclaxenhancesantitumoreffectinamlviacmycbclxlmcl1tripletargeting AT shuangyueli combinationofdihydroartemisininandvenetoclaxenhancesantitumoreffectinamlviacmycbclxlmcl1tripletargeting AT peipeiye combinationofdihydroartemisininandvenetoclaxenhancesantitumoreffectinamlviacmycbclxlmcl1tripletargeting AT jiayinglian combinationofdihydroartemisininandvenetoclaxenhancesantitumoreffectinamlviacmycbclxlmcl1tripletargeting AT yinglu combinationofdihydroartemisininandvenetoclaxenhancesantitumoreffectinamlviacmycbclxlmcl1tripletargeting |